摘要
目的:运用成本-效果分析方法评价4种高血压药物治疗方案的经济学效果。方法:对195例患者分别采用进口苯那普利(A组)、国产苯那普利(B组)、进口厄贝沙坦胶囊(C组)、国产厄贝沙坦片(D组)为主要降压药的治疗方案进行成本-效果分析。结果:4组临床疗效差异无显著性(P>0.05),临床疗效分别为:93.75%,92.16%,93.48%,92.00%。4组的降压总成本分别为:A组总成本为206.24元;B组总成本为113.68元;C组总成本为306.32元;D组降压总成本为164.64元。结论:从药物经济学角度看,国产长效ACEI-苯那普利为较佳选择。国产长效ACEI和ARB方案相对进口产品更合算。
Objective： Using the cost - effectiveness analysis to evaluate the pharmacoeconomic effects of four therapeutic regimens for community primary hypertension. Methods： The costeffectiveness analysis was performed on the therapeutic regimens of 195 patients with primary hypertension, who were taking imported benazepril （group A） ,domestic benazepril （ group B） , imported irbesartan capsules （group C）, or domestic irbesartan tablets （group D） as the main treatment for their primary hypertension respectively. Results：There was no significant difference on the clinical therapeutic effects between the four groups （P 〉 0.05）. For the group A, B, C, and D groups ,the clinical therapeutic effects were 93.75% ,92. 16%, 93.48%, and 92. 00%respectively. The total antihypertensive therapy cost in the four groups are： RMB 206.24 Yuan for group A, RMB 113.68 Yuan for group B, RMB 306. 32 Yuan for group C, and RMB 164. 64 Yuan for group D, respectively. Conclusions ： With regard to the pharmacoeconomics, the domestic long - acting ACE inhibitor, benazepril, will be a better therapeutic regimen for the the community patients with primary hypertension. Compared with the samilar imported products, the therapeutic regimen of domestic long- acting ACE inhibitors or ARB will be more economical.
基金
广州市天河区科技计划项目(编号06KW012)
关键词
高血压
药物经济学
成本
效果分析
Hypertension
Pharmacoeconomics
Cost - effectiveness analysis
